Legend Biotech
Most recent annual filing: 2026-03-20
- Legend Biotech corporate update2026Legend Biotech corporate update, 2026, routine
- LB2501 interim2H 2026LB2501 interim, 2H 2026, notable
- TaVec in vivo platform filing2H 2026TaVec in vivo platform filing, 2H 2026, notable
- anito-cel Arcellx PDUFA dateDec 23, 2026anito-cel Arcellx PDUFA date, Dec 23, 2026, thesis-defining
- Janssen Funding Advance corporate update1Q 2027Janssen Funding Advance corporate update, 1Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
Biotech Distilled coverage (2)
- 2026-08-12 UPDATE: Legend Biotech (LEGN) - The Margin Line Answers Back 🔒 Paid
- 2026-07-29 Legend Biotech (LEGN) — Scientific Deep Dive for CARVYKTI® (cilta-cel) and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.